3Anna Liberek,Anna Szaflarska-Poplawska,Maria Korzon,Gra(?)yna (?)uczak,Magdalena Góra-Gebka,Ewa (?)o(s|')-Rycharska,Wanda Bako,Mieczyslawa Czerwionka-Szaflarska.Lamivudine therapy for children with chronic hepatitis B[J].World Journal of Gastroenterology,2006,12(15):2412-2416. 被引量：4
二级参考文献14
1Guang-Bi Yao, Zhen-Yu Cui, Bao-En Wang, Ji-Lu Yao and Min-De Zeng Shanghai, China Shanghai Jing-An Qu Central Hospital, Shanghai 200040, China ,Beijing Ditan Hospital, Beijing 100011 , China Beijing Friendship Hospital, Beijing 100050, China ,3rd Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Chinaand Shanghai Renji Hospital, Shanghai Second Medical University, Shanghai 200001 , China.A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B[J].Hepatobiliary & Pancreatic Diseases International,2004,3(2):188-193. 被引量：11
2Bendele RA,Richardson FC.Adefovir nephrotoxicity and mitochondrial DNA depletion[].Human Pathology.2002
3Ho ES,Lin DC,Mendel DB,et al.Cytotoxicity of antiviral nucle-otides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1[].Journal of the American Society of Nephrology.2000
4Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmaco- kinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks[].Antimicrobial Agents and Chemotherapy.2001
5Delaugerre C,Marcelin AG,Thibault V,Peytavin G,et al.Human immunodeficiency virus(HIV) Type 1 reverse transcriptase resistance mutation in hepatitis B virus(HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine[].Antimicrobial Agents and Chemotherapy.2002
6Nobel S,Goa KL.Adefovir dipivoxil[].Drugs.1999
7Julander JG,Sidwell RW,Morrey JD.Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus[].Antiviral Research.2002
8Yang H,Westland CE,Delaney WE,et al.Resistance surveillance in chronic hepatitis B patients treated with Adefovir dipivoxil for up to 60 weeks[].Hepatology.2002
9Perrillo R. Schiff E.Yoshida E,et al.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants[].Hepatology.2000
10Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[].The New England Journal of Medicine.2003
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
4李家泰.临床药理学[M].北京:人民卫生出版社,2007.
5Davey S. State of the World's Vaccines and Immunization [M]. Geneva:World Health organization,1996:76.
6Alexopoulou A, karayiannis P, Hadziyamis SJ,et al. Whole genome analysis B virus form four case of folminant hepatitis: genetic varizbiliby and its potential role in disease pathogeniel- ty[J]. J Viral Hepatol,1996,3(4):173-181.
7Kuwahara R, Kumashiro R, Murashima S, et al. Precore stop eodon mutation of hepatitis B virus is associated wit h low breakthrough rate following longterm lamivudine thera- py[J]. J Gast roenterol Hepatol,2005,20(6) :844-849.
8Chen CH, Lee CM, Lu SN,et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-pos- itive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy[J]. J Hepatol, 2006,44 (1) 76-82.
9Lok AS, Lai CL, Leung N, et al. Long-term safety of lami- vudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003,125 (6) :1714-1722.
10Mareellin P, Chang TT, Lira SG, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hep- atitisB[J]. N Engl J Med,2003,348(9):808-816.
